Sanofi PRO Questionnaires

Atopic Dermatitis Control Tool (ADCT)

Description

Last Update: May 2020

Objective

To measure Atopic Dermatitis (AD) disease control

Targeted Population

  • Atopic Dermatitis
  • Adult patients

Development

  • Information from literature review for concepts and already existing instruments
  • Involvement of clinical experts
  • Concept elicitation: Involvement of 16 adult AD patients in face-to-face semi-structured interviews
  • Development of a first 11-item draft instrument reduced to 6 items following Cognitive debriefing interviews with 16 (two rounds of 8 patients) adult AD patients

Content and structure 

The final version of the instrument (V1) includes 6 items, with a 7-day recall period:

  • Overall severity of symptoms
  • Frequency of intense episodes of itching
  • Severity of bother
  • Frequency of sleep impact
  • Severity of daily activities impact
  • Severity of mood or emotions impact

Validation

The ADCTv1 was validated in 270 adult patients with AD. Psychometric validation demonstrated good reliability and validity:

  • No floor or ceiling effects for response distributions, strong (r ≥0.80) inter-item correlations
  • Robust construct validity:
  • Strong internal consistency reliability
    • Good convergent and divergent validity
    • Good clinical validity:  ADCT able to discriminate between severity levels  

 

Each item is scored from 0 (none) to 4 (extreme). A total score of 7 or more points (derived by adding item scores) was identified as an optimum threshold to identify patients whose AD is “not in control”.

Copyright Holders

Sanofi and Regeneron Pharmaceuticals Inc.


Review copy


Languages

Original Language(s)

  • English for the USA

List of Translations

ADCT

Arabic for Israel*
Arabic for Kuwait*
Arabic for Saudi Arabia*
Arabic for the United Arab Emirates*
Bulgarian for Bulgaria*
Croatian for Croatia*
Czech for Czech Republic*
Danish for Denmark*
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Australia*
English for Canada*
English for Ireland*
English for the UK*
English for the USA
Estonian for Estonia*
Finnish for Finland*
French for Belgium*
French for Canada*
French for France*
French for Switzerland*
German for Austria*
German for Germany*
German for Switzerland*
Greek for Greece*
Hebrew for Israel*
Hungarian for Hungary*
Italian for Italy*
Japanese for Japan*
Korean for South Korea*
Mandarin for China*
Mandarin for Taiwan*
Norwegian for Norway*
Polish for Poland*
Portuguese for Brazil*
Portuguese for Portugal*
Romanian for Romania*
Russian for Estonia*
Russian for Israel*
Russian for Russia*
Slovak for Slovakia*
Slovenian for Slovenia*
Spanish for Argentina*
Spanish for Colombia*
Spanish for Mexico*
Spanish for Spain*
Spanish for the USA*
Swedish for Finland*
Swedish for Sweden*
Turkish for Turkey*
* Performed by Mapi

Conditions of use


References

Bibliographic references of the original questionnaire

Pariser D, Simpson E, Gadkari A, Bieber T, Margolis J,Brown M, Nelson L, Mahajan P, Reaney M, Guillemin I, Mallya U, Eckert L. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). 2019 Nov 19; 367-376 (Full text article)

Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019 Nov 6;19(1):15 (Full text article)

Need more information on this questionnaire? Consult ePROVIDE™